AstraZeneca PLC closed 20.36% short of its 52-week high of £133.88, which the company achieved on September 3rd.

A new AI-driven framework, MapDiff, enhances inverse protein folding accuracy, accelerating the design of proteins for ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, to ...

AstraZeneca PLC has acquired a significant stake of 15.86% in Niox Group PLC, according to a recent company filing. This move ...

(Reuters) -Drugmaker Eli Lilly is in advanced talks to acquire gene-editing startup Verve Therapeutics for up to $1.3 billion ...

An AI approach developed by researchers from the University of Sheffield and AstraZeneca, could make it easier to design ...

(NASDAQ:SRPT) plunged to $19.91, down $16.27, or almost 45%, on word of a second death by acute liver failure (ALF) with Elevidys (delandistrogene moxeparvovec), the approved gene therapy for patients ...

AstraZeneca PLC closed 19.20% below its 52-week high of £133.88, which the company achieved on September 3rd.

Scientists have developed a new machine learning framework that has shown the potential to be more accurate at inverse ...

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...

Demand is rising for AI-powered robots that can clean offices or roll around moving items from one part of a building to ...

AstraZeneca is making a bold move. The drug giant just teamed up with CSPC in a deal worth up to $5.3 billion. The goal? To ...